Your browser does not support iframes.
N&O 100
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
AGENUS
(NQ:
AGEN
)
4.070
USD
-0.050 (-1.21%)
Official Closing Price
/ Updated:
8:10 PM EDT, May 24, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
0
Open
4.100
Bid (Size)
4.050 (10500)
Ask (Size)
4.060 (500)
Prev. Close
4.120
Today's Range
4.050 - 4.190
52wk Range
3.370 - 5.990
Shares Outstanding
28,304,985
Dividend Yield
N/A
Top News
More News
Agenus Announces Initiation of Enrollment in NCI-Sponsored Randomized Trial of Prophage G-200 Vaccine With Avastin in Treatment of Brain Tumors
May 22, 2013
Study Seeking to Enroll 222 Patients; Largest Vaccine Trial Ever Funded by NCI in Brain Tumors and the Largest Cancer Vaccine Study Ever Conducted in Combination With Avastin
Read More
from
GlobeNewswire News Releases
1 Stock to Buy, 1 Stock to Short: Small-Cap Pharma
May 17, 2013
Read More
category
NASDAQ:PPHM
,
NASDAQ:AGEN
from
InvestorPlace - Latest Headlines
More News
Read More
Mentor Capital Cancer Immunotherapy Index Gains 28% During First Quarter of 2013
May 02, 2013
from
Business Wire News Releases
Agenus (AGEN) Sees Volatility Following Phase 2 Data on Prophage
May 01, 2013
from
StreetInsider.com News Articles
Positive Phase 2 Data from Agenus' Brain Cancer Vaccine Presented at Plenary Session of American Academy of Neurological Surgeons Meeting
May 01, 2013
from
GlobeNewswire News Releases
Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billion
April 29, 2013
category
THLD
,
CLDX
,
Scott Matusow
, and 2 more.
from
Bio-Wire.Com
Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billion
April 29, 2013
category
investing
,
catalyst trades
,
ACAD
, and 9 more.
from
Bio-Wire.Com
Agenus 8 Near term Data Drivers with a Market Opportunity over $17 Billion dollars
April 29, 2013
category
Pharmaceuticals
from
Trefis
Quickly Approaching Biopharma Catalyst Events
April 24, 2013
category
SRPT
,
Scott Matusow
,
INSM
, and 2 more.
from
Bio-Wire.Com
Quickly Approaching Biopharma Catalyst Events
April 24, 2013
category
Pharmaceuticals
from
Trefis
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here
Your browser does not support iframes.